Navigation Links
Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial
Date:11/5/2011

policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and ef
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
2. Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
3. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
4. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
5. XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
6. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
7. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
8. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
9. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
10. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
11. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  With all the daily obstacles facing physicians these ... keep patients healthy should be easy. Unfortunately, it isn,t ... Care Act continues to affect the way physicians are ... more important than ever that medical practices have open ... with for patient care. Each year, cloud-based ...
(Date:5/27/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/hxhwtv/asia_pacific ) has ... Market - Growth, Trends And Forecasts (2014 - 2019)" ... Asia Pacific market for Fluoroscopy ... 2014 to 2020 Fluoroscopy is the imaging ... of the interior of the body. The imaging team ...
(Date:5/27/2015)... May 27, 2015 Doctors from the ... Children,s National Health System are the first ... treat osteoid osteoma, a benign but painful bone tumor ... an experimental magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) method. ... Niyati Shah , have been treated successfully in ...
Breaking Medicine Technology:Physicians Seek Payer Inclusion, Not Impediment 2Physicians Seek Payer Inclusion, Not Impediment 3Asia Pacific Fluoroscopy Market Trends and Forecasts 2014 - 2019 2Children's National first in US to destroy bone tumors with incisionless surgery 2Children's National first in US to destroy bone tumors with incisionless surgery 3Children's National first in US to destroy bone tumors with incisionless surgery 4
... May 5, 2011 Stereotaxis, Inc. (NASDAQ: ... entered into a new strategic collaboration with Biosense ... Solutions. This agreement marks the broadest and most ... Under the new agreement, Stereotaxis has granted ...
... 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: ... targeting the extracellular matrix , today announced that management ... Health Care Conference in Las Vegas. The presentation is scheduled ... To listen to the live webcast or a replay of ...
Cached Medicine Technology:Stereotaxis and Biosense Webster Announce New Strategic Collaboration 2Stereotaxis and Biosense Webster Announce New Strategic Collaboration 3Stereotaxis and Biosense Webster Announce New Strategic Collaboration 4Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12 2
(Date:5/27/2015)... 2015 Continuing its commitment to finding ... in the community, SmartPractice® donated $25,000 to ... Lincoln). SmartPractice Vice President of Human Resources Meg Mosher ... $25,000 check to Paulla Miller, Sherry Gage, Dr. Linda ... Research Center on April 30. The center is located ...
(Date:5/27/2015)... Austin, Texas (PRWEB) May 27, 2015 ... margins are getting tighter, it can be challenging for ... technology for cutting edge treatments. , Austin-based ... problem, with minimally invasive, mobile medical therapies for clinically ... medical portfolio with the acquisition of Laser Ventures, ...
(Date:5/27/2015)... May 27, 2015 The new ... include: Why investors should consider oil and gas investing, ... why wells are drilled, industry news, IRA investing, definitions ... 32 years of knowledge and experience is now in ... community to be able to access 24 hours a ...
(Date:5/27/2015)... In support of a new ... the Journal of American Geriatrics Society about the link ... Bedford Commons OB-GYN P.A . is reiterating the nutritional ... , To examine the relationship between diet soda ... Longitudinal Study of Aging (SALSA) tracked the soda consumption ...
(Date:5/27/2015)... ABILENE, Texas (PRWEB) May 27, 2015 ... addition of three FDA-approved dermal filler treatments in Abilene, ... designed to reduce the appearance of glabellar lines, better ... lines. Belotero Balance® is designed to treat smoker’s ... mouth to the chin, while Radiesse® improves the appearance ...
Breaking Medicine News(10 mins):Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:The MedSpa at Hendrick Introduces Xeomin®, Belotero Balance® and Radiesse® Injectables 2
... back we had carried a story about Wal-mart’s foray into ... pilot project which involved the lease of medical space in ... functioning at the Wal mart stores across 12 different states. ... World Health Care Congress, Leo Scott, the President and CEO ...
... discloses that nearly 65% of children from grade 7 to ... using artificial tanning equipments. ,The society is voicing ... under the age of 18 be prevented from tanning using ... is one of the most common forms of cancer in ...
... team of researchers at the John Hopkins Hospital in the US ... the PSA to detect prostate cancer.// ,The new test ... a simple blood test. ,Prostate cancer, the most ... of medicine. Physicians are unsure how to find it and when ...
... does not protect older women against cognitive decline, finds ... ,Identifying ways to prevent dementia is a public health ... may protect against dementia, but data from randomised studies ... US decided to test the effect of long term ...
... it is willing to proceed with the registration of a ... the Thai// government will halt its plans for a compulsory ... and will sell it to the Thai government for $1000 ... with the Thai government since January 2007, when plans for ...
... that took place last week at the Virginia Tech Many ... to formulate some// measures to avert this kind of a ... mentally ill, before they harm themselves and the others. A ... parents without the fear of infringing the privacy laws if ...
Cached Medicine News:Health News:Artificial Tanning Causes Concern 2Health News:New blood test to detect prostate cancer 2Health News:Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt 2Health News:Measures Needed to Avert Another Bloodbath 2
... STaK-Chex, a whole blood assayed hematology ... five-part white cell differential available with the ... unique product has 14-day open-vial stability, 105-day ... normal and high levels. The 4.0ml pierceable ...
Antelys Peek Lumbar Technologies provides a range of varied heights and angles to correct lumbar lordosis and the associated sagital balance....
Spectrum Dynamics empowers Nuclear Imaging with the SmartR Technology,of the D-SPECT Cardiac Imaging System. The D-SPECT is powered by BroadView Technology to provide unprecedented throughput, whil...
For immediate disabling...
Medicine Products: